JANESVILLE, Wis., Sept. 4, 2019 – SHINE Medical Technologies LLC today announced the appointment of Harrie Buurlage as vice president, European operations. Mr. Buurlage will oversee all of SHINE's activities in Europe, including the company's siting, construction and operation of a medical isotope production facility there.
Mr. Buurlage brings more than 25 years of experience in the nuclear medicine industry to his new role at SHINE, including positions in management, operations, and sales and marketing.
Mr. Buurlage was chief operating officer and then managing director of NRG, an international nuclear service provider, in the Netherlands. Among other things, Mr. Buurlage oversaw the operation of all of NRG's nuclear installations, including the Dutch High Flux medical isotope production facility in Petten, which produces isotopes used in more than 30,000 patient treatments a day. He led a multi-year transition of the company from a science institute to a more robust health care organization.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Before joining NRG, Mr. Buurlage was global director of manufacturing for Covidien USA, now Curium Pharma, where he was responsible for radiopharmaceutical isotope manufacturing and distribution at facilities in the Netherlands, United Kingdom and United States. Mr. Buurlage oversaw the addition of a new reactor to Covidien's supply chain in only nine months. He also drove logistical improvements in Europe, the Middle East and Africa, and was global chairman of the company's nuclear medicine council.
Earlier in this career, Mr. Buurlage spent nearly 15 years at Mallinckrodt, where he served in positions of increasing responsibility at Petten, including managing director of Mallinckrodt Medical (MM) B.V. and director of EMEA operations.
"It is well known that current European producers of medical isotopes are planning to cease operations in the next several years, and SHINE is excited to be in a position to ensure that Europeans have uninterrupted access to the life-saving products our team and technology can provide," said Greg Piefer, founder and CEO of SHINE. "Harrie's experience in the nuclear industry and European market, and his management, operations and logistics expertise will be invaluable to SHINE as we execute our plan there. We look forward to working with Harrie to make a SHINE European presence a reality, and provide for a robust European and global supply chain."
Mr. Buurlage studied applied physics at the University of Groningen. He earned certification as a radiation safety officer at the University of Leiden, the highest-level certification of its kind in Europe, which allows holders to supervise large, complex nuclear sites.